– USA, PA – ArriVent BioPharma, Inc. (NASDAQ: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, announced the appointment of Dr. John Hohneker (M.D.) to its Board of Directors, bringing over 30 years of experience in biopharmaceutical leadership and drug development.
About Dr. John Hohneker
Dr. John Hohneker serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics.
Most recently, Dr. Hohneker served as President and CEO of Anokion SA. Before this role, Dr. Hohneker was President of Research and Development at Forma Therapeutics, Inc., where he guided the company’s transition from a discovery-stage biotech to a clinical-stage company. Previously, Dr. Hohneker held various leadership roles during his 14 years at Novartis AG, including SVP and Global Head of Development, Immunology, and Dermatology. During his tenure at Novartis, he played a key role in the development, approval, and commercialization of several products.
Dr. Hohneker earned his B.A. in chemistry from Gettysburg College and his M.D. from the University of Medicine and Dentistry of New Jersey at Rutgers Medical School.
About ArriVent
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization.
For more information: https://arrivent.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.